Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32684974 | 0.94 | KDM4E (0.42) | HTTKDM4EGLAKMT2ASMN1; SMN2 | |
| SCHEMBL21355057 | 0.94 | KDM4E (0.42) | HTTKDM4EGLAKMT2ASMN1; SMN2 | |
| SCHEMBL24323731 | 0.86 | F2R (0.38) | HTTKDM4EGLAKMT2ASMN1; SMN2 | |
| SCHEMBL29951949 | 0.86 | DDB1 (0.47) | HTTKDM4EGLAKMT2ASMN1; SMN2 | |
| SCHEMBL29952339 | 0.85 | — | — | |
| SCHEMBL29955701 | 0.83 | HTR3A (0.47) | DDB1CRBN | |
| SCHEMBL29958145 | 0.81 | KCNJ1 (0.35) | HTTKDM4EGLAKMT2ASMN1; SMN2 | |
| SCHEMBL31370997 | 0.80 | PRMT5 (0.38) | HTTKDM4EGLAKMT2ASMN1; SMN2 | |
| SCHEMBL29820350 | 0.79 | KCNJ1 (0.33) | HTTKDM4EGLAKMT2ASMN1; SMN2 | |
| SCHEMBL24666229 | 0.79 | KCNJ1 (0.33) | HTTKDM4EGLAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956985-A | Inhibitors of glycogen synthase 1 (GYS 1) and methods of use thereof | 梅兹治疗公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | HTT 2663/4885KDM4E 2617/4885GLA 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.